# PepGen Inc.: financial statements, quarterly

PEPG · Nasdaq · CIK 1835597 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pepg.md) · [Financials](/companies/pepg/financials.md) · [Filings](/companies/pepg/filings.md) · [Insiders](/companies/pepg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pepg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [20.5](/filings/0000950170-24-122821.md) | [16.3 d](/filings/0000950170-25-025226.md) | [14.7](/filings/0000950170-25-066414.md) | [25.1](/filings/0001193125-25-174979.md) | [17.7](/filings/0001193125-25-276001.md) | [19.0 d](/filings/0001193125-26-091536.md) | [25.4](/filings/0001193125-26-219375.md) | [18.4](/filings/0001193125-26-336754.md) | [13.4](/filings/0001193125-25-276001.md) | [13.9 d](/filings/0001193125-26-091536.md) | [13.0](/filings/0001193125-26-219375.md) | [12.5](/filings/0001193125-26-336754.md) |
| Operating income | $m | [(24.8)](/filings/0000950170-24-122821.md) | [(20.8) d](/filings/0000950170-25-025226.md) | [(19.8)](/filings/0000950170-25-066414.md) | [(30.4)](/filings/0001193125-25-174979.md) | [(23.2)](/filings/0001193125-25-276001.md) | [(24.3) d](/filings/0001193125-26-091536.md) | [(31.3)](/filings/0001193125-26-219375.md) | [(23.9)](/filings/0001193125-26-336754.md) | [(18.7)](/filings/0001193125-25-276001.md) | [(19.7) d](/filings/0001193125-26-091536.md) | [(18.9)](/filings/0001193125-26-219375.md) | [(18.9)](/filings/0001193125-26-336754.md) |
| Income tax | $m | not reported | not reported | not reported | [0.0](/filings/0001193125-25-174979.md) | [0.0](/filings/0001193125-25-276001.md) | [(0.6) d](/filings/0001193125-26-091536.md) | [0.0](/filings/0001193125-26-219375.md) | [0.0](/filings/0001193125-26-336754.md) | [0.0](/filings/0001193125-25-276001.md) | [0.0 d](/filings/0001193125-26-091536.md) | [0.0](/filings/0001193125-26-219375.md) | [0.0](/filings/0001193125-26-336754.md) |
| Net income | $m | [(23.3)](/filings/0000950170-24-122821.md) | [(19.5) d](/filings/0000950170-25-025226.md) | [(18.0)](/filings/0001193125-25-276001.md) | [(28.3)](/filings/0001193125-25-276001.md) | [(21.4)](/filings/0001193125-25-276001.md) | [(22.2) d](/filings/0001193125-26-091536.md) | [(30.2)](/filings/0001193125-26-336754.md) | [(23.1)](/filings/0001193125-26-336754.md) | [(18.0)](/filings/0001193125-25-276001.md) | [(18.3) d](/filings/0001193125-26-091536.md) | [(17.8)](/filings/0001193125-26-336754.md) | [(17.8)](/filings/0001193125-26-336754.md) |
| Diluted EPS | $ per share | [(0.98)](/filings/0000950170-24-122821.md) | not reported | [(0.63)](/filings/0000950170-25-066414.md) | [(0.87)](/filings/0001193125-25-174979.md) | [(0.66)](/filings/0001193125-25-276001.md) | not reported | [(0.92)](/filings/0001193125-26-219375.md) | [(0.70)](/filings/0001193125-26-336754.md) | [(0.52)](/filings/0001193125-25-276001.md) | not reported | [(0.26)](/filings/0001193125-26-219375.md) | [(0.26)](/filings/0001193125-26-336754.md) |
| Basic EPS | $ per share | [(0.98)](/filings/0000950170-24-122821.md) | not reported | [(0.63)](/filings/0000950170-25-066414.md) | [(0.87)](/filings/0001193125-25-174979.md) | [(0.66)](/filings/0001193125-25-276001.md) | not reported | [(0.92)](/filings/0001193125-26-219375.md) | [(0.70)](/filings/0001193125-26-336754.md) | [(0.52)](/filings/0001193125-25-276001.md) | not reported | [(0.26)](/filings/0001193125-26-219375.md) | [(0.26)](/filings/0001193125-26-336754.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [130](/filings/0000950170-24-122821.md) | [80.8](/filings/0000950170-25-025226.md) | [134](/filings/0000950170-25-066414.md) | [66.1](/filings/0001193125-25-174979.md) | [42.3](/filings/0001193125-25-276001.md) | [49.4](/filings/0001193125-26-091536.md) | [43.6](/filings/0001193125-26-219375.md) | [35.1](/filings/0001193125-26-336754.md) | [143](/filings/0001193125-25-276001.md) | [60.5](/filings/0001193125-26-336754.md) | [42.2](/filings/0001193125-26-219375.md) | [22.8](/filings/0001193125-26-336754.md) |
| Current assets | $m | [133](/filings/0000950170-23-060702.md) | [113](/filings/0000950170-25-025226.md) | [178](/filings/0000950170-24-059519.md) | [165](/filings/0000950170-24-093351.md) | [142](/filings/0000950170-24-122821.md) | [124](/filings/0001193125-26-091536.md) | [101](/filings/0000950170-25-066414.md) | [77.5](/filings/0001193125-25-174979.md) | [166](/filings/0001193125-25-276001.md) | [151](/filings/0001193125-26-336754.md) | [134](/filings/0001193125-26-219375.md) | [120](/filings/0001193125-26-336754.md) |
| Total assets | $m | [164](/filings/0000950170-23-060702.md) | [143](/filings/0000950170-25-025226.md) | [207](/filings/0000950170-24-059519.md) | [194](/filings/0000950170-24-093351.md) | [170](/filings/0000950170-24-122821.md) | [151](/filings/0001193125-26-091536.md) | [127](/filings/0000950170-25-066414.md) | [102](/filings/0001193125-25-174979.md) | [190](/filings/0001193125-25-276001.md) | [174](/filings/0001193125-26-336754.md) | [156](/filings/0001193125-26-219375.md) | [141](/filings/0001193125-26-336754.md) |
| Current liabilities | $m | [21.0](/filings/0000950170-23-060702.md) | [17.5](/filings/0000950170-25-025226.md) | [11.3](/filings/0000950170-24-059519.md) | [22.1](/filings/0000950170-24-093351.md) | [16.8](/filings/0000950170-24-122821.md) | [16.7](/filings/0001193125-26-091536.md) | [20.4](/filings/0000950170-25-066414.md) | [16.4](/filings/0001193125-25-174979.md) | [12.6](/filings/0001193125-25-276001.md) | [12.6](/filings/0001193125-26-336754.md) | [9.0](/filings/0001193125-26-219375.md) | [9.0](/filings/0001193125-26-336754.md) |
| Total liabilities | $m | [38.4](/filings/0000950170-23-060702.md) | [34.6](/filings/0000950170-25-025226.md) | [28.0](/filings/0000950170-24-059519.md) | [38.5](/filings/0000950170-24-093351.md) | [32.8](/filings/0000950170-24-122821.md) | [32.3](/filings/0001193125-26-091536.md) | [35.6](/filings/0000950170-25-066414.md) | [31.1](/filings/0001193125-25-174979.md) | [26.9](/filings/0001193125-25-276001.md) | [26.5](/filings/0001193125-26-336754.md) | [22.3](/filings/0001193125-26-219375.md) | [21.9](/filings/0001193125-26-336754.md) |
| Shareholders' equity | $m | [126](/filings/0000950170-24-122821.md) | [108](/filings/0001193125-26-091536.md) | [179](/filings/0001193125-25-276001.md) | [155](/filings/0001193125-25-276001.md) | [137](/filings/0001193125-25-276001.md) | [119](/filings/0001193125-26-336754.md) | [91.8](/filings/0001193125-26-336754.md) | [71.2](/filings/0001193125-26-336754.md) | [163](/filings/0001193125-25-276001.md) | [147](/filings/0001193125-26-336754.md) | [134](/filings/0001193125-26-336754.md) | [120](/filings/0001193125-26-336754.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(16.7) d](/filings/0000950170-24-122821.md) | [(19.4) d](/filings/0000950170-25-025226.md) | [(22.5)](/filings/0000950170-25-066414.md) | [(16.4) d](/filings/0001193125-25-174979.md) | [(24.0) d](/filings/0001193125-25-276001.md) | [(19.5) d](/filings/0001193125-26-091536.md) | [(22.9)](/filings/0001193125-26-219375.md) | [(23.6) d](/filings/0001193125-26-336754.md) | [(19.3) d](/filings/0001193125-25-276001.md) | [(15.8) d](/filings/0001193125-26-091536.md) | [(18.4)](/filings/0001193125-26-219375.md) | [(15.8) d](/filings/0001193125-26-336754.md) |
| Capital expenditure | $m | [0.2 d](/filings/0000950170-24-122821.md) | [0.2 d](/filings/0000950170-25-025226.md) | [0.1](/filings/0000950170-25-066414.md) | [0.0 d](/filings/0001193125-25-174979.md) | [0.2 d](/filings/0001193125-25-276001.md) | [0.2 d](/filings/0001193125-26-091536.md) | [0.1](/filings/0001193125-26-219375.md) | [0.0 d](/filings/0001193125-26-336754.md) | [0.1 d](/filings/0001193125-25-276001.md) | [(0.0) d](/filings/0001193125-26-091536.md) | [0.0](/filings/0001193125-26-219375.md) | [0.0 d](/filings/0001193125-26-336754.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [23.6](/filings/0000950170-23-060702.md) | [23.8](/filings/0000950170-24-059519.md) | [23.8](/filings/0000950170-24-093351.md) | [23.8](/filings/0000950170-24-122821.md) | [28.7](/filings/0000950170-25-066414.md) | [32.5](/filings/0001193125-25-174979.md) | [32.6](/filings/0001193125-25-276001.md) | [32.7](/filings/0001193125-26-219375.md) | [32.7](/filings/0001193125-26-336754.md) | [34.4](/filings/0001193125-25-276001.md) | [69.1](/filings/0001193125-26-219375.md) | [69.2](/filings/0001193125-26-336754.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 69,259,517 at 2026-08-02, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336754.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.